FDA hands over full approval to AZ’ Tagrisso
US regulators have issued a full approval of AstraZeneca’s lung cancer drug Tagrisso on the back of a strong progression-free survival (PFS) benefit observed in a late-stage trial.
Read More
Tag: TKI
Data backs broader use of Pfizer’s Sutent in kidney cancer
A Phase III study pitting adjuvant use of Pfizer’s Sutent against a placebo in patients with kidney cancer has met its primary endpoint of showing improved disease-free survival (DFS) in those taking the drug.
Read More
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
